Edition:
India

Luye Pharma Group Ltd (2186.HK)

2186.HK on Hong Kong Stock

4.66HKD
27 Oct 2020
Change (% chg)

HK$-0.11 (-2.31%)
Prev Close
HK$4.77
Open
HK$4.75
Day's High
HK$4.80
Day's Low
HK$4.65
Volume
8,013,096
Avg. Vol
16,214,445
52-wk High
HK$6.88
52-wk Low
HK$3.50

Summary

Name Age Since Current Position

Dian Bo Liu

54 2016 Executive Chairman of the Board, Chief Executive Officer

Rong Bing Yang

54 2015 Vice Executive Chairman of the Board

Yuan Chong Liu

56 2012 Chief Financial Officer

You Xin Li

58 2014 Senior Vice President, Head - Research and Development

Yun Li Xue

56 2014 Senior Vice President, General Manager of Shandong Luye

Hua Jiang

42 Vice President, Head - International Business

Hui Xian Yuan

61 Executive Director

Yuan Yuan Zhu

39 2014 Executive Director

Siu Kuen Lai

Company Secretary

Rui Lin Song

58 2017 Non-Executive Director

Sze Chung Choy

61 2014 Non-Executive Independent Director

Man Kit Leung

66 2014 Non-Executive Independent Director

Yuk Lam Lo

71 2014 Non-Executive Independent Director

Hua Qiao Zhang

56 2014 Non-Executive Independent Director

Biographies

Name Description

Dian Bo Liu

Mr. Liu Dian Bo is an Executive Chairman of the Board, Chief Executive Officer of Luye Pharma Group Ltd. He was appointed as a director of the Company (“Director”) in July 2003. As our Executive Chairman, Mr. Liu is responsible for the overall management, operations and the charting and reviewing of corporate directions and strategies of our Group. Prior to founding our Group, Mr. Liu was a teacher at Yantai Teacher’s College from 1985 to 1989. From 1989 to 1993, Mr. Liu was the general manager of Penglai Huatai Pharmaceutical Co. Ltd. From 1994 to 1999, Mr. Liu was the chairman cum general manager of (Shandong Luye Pharmaceutical Co., Ltd.) (“Shandong Luye”). From 1999 to the incorporation of our Company in 2003, Mr. Liu was the chairman cum president of Shandong Luye. Mr. Liu obtained a Medical Diploma from Yishui Special Medical College (now known as Shandong Medical College) in July 1985. Mr. Liu is the executive chairman of Shandong Luye and Beijing WBL Peking University Biotech Co., Ltd. (“Beijing WPU”), and a director of the following main subsidiaries of our Company: Yantai Luye Drugs Trading Co., Ltd. (“Luye Trading”), Sichuan Luye Buoguang Pharmaceutical Co., Ltd., Shandong Luye Natural Drug R&D Co. Ltd., Shanghai Ge Lin Li Fu Business Consulting Co. Ltd., AsiaPharm Investments Limited, AsiaPharm Biotech Pte. Ltd., Luye Biotech (Singapore) Pte. Ltd. and A-Bio Pharma Pte. Ltd.. Mr. Liu is a director of each of Luye Life Sciences Group Ltd. (“Luye Group”), Luye Pharma Holdings Ltd. (“Luye Pharma Holdings”), LuYe Pharmaceutical International Co., Ltd. (“Luye Pharma Intl”), LuYe Pharmaceutical Investment Co., Ltd. (“Luye Pharma Investment”), Shorea LBG, Ginkgo (PTC) Limited, and Nelumbo Investment Limited.

Rong Bing Yang

Mr. Yang Rong Bing is Vice Executive Chairman of the Board of Luye Pharma Group Ltd. Mr. Yang was appointed as an Executive Director on 1 March 2007 and was previously a Non-Executive Director from July 2003. Mr. Yang was appointed as a vice executive chairman of the Board with effect from 30 March 2015. Mr. Yang has also been a non-executive director of Shandong Luye since 2000. Prior to that, Mr. Yang was with Jiangsu Xuzhou Bio- Chemical Pharmaceutical Factory from 1988 to 1994 where he worked as an assistant factory head. In 1994, Mr. Yang joined Shandong Luye as a deputy general manager and from 1999 to 2000, he was the chief sales executive and executive director of Shandong Luye. Mr. Yang obtained a Bachelor’s degree in Science from Beijing Normal University in July 1988. Mr. Yang is the executive chairman of Nanjing Luye Pharmaceutical Co., Ltd. (“Nanjing Luye”) and a director of the following main subsidiaries of our Company: Shandong Luye, Luye Trading and Nanjing Luye. Mr. Yang is a director of each of Luye Group, Luye Pharma Holdings, Luye Pharma Intl and Luye Pharma Investment.

Yuan Chong Liu

Mr. Liu Yuan Chong is Chief Financial Officer of the Company. He started as the accountant-in-charge at our finance department, and was promoted to chief of the finance department in 2005 and to our Chief Financial Officer in 2012. Prior to joining our Group, he was the head of accounting of Yantai Alternator Plant. He also taught at Yantai Business Vocational Secondary School from September 1983 until September 1986. From 1980 to 1983, he was employed by Shangdong Laiyang Biochemical Pharmaceutical Factory. Mr. Liu received a Post-Graduate Certificate in Financial Management from Peking University in October 2006.

You Xin Li

Dr. Li You Xin, Ph.D. is Senior Vice President, Head - Research and Development of Luye Pharma Group Ltd. Dr. Li has extensive experience in drug design. He is responsible for a number of our R&D platforms including our long-acting and extended release technology and targeted drug delivery platforms. Under Dr. Li’s leadership, the Company was awarded the State Key Laboratory of Long-acting and Targeting Drug Delivery System. Dr. Li is also a professor at the College of Life Sciences of Jilin University. Prior to joining our Group, he was a senior scientist officer at Schwarz Pharma AG. He was also a Research Fellow of Alexandar von Humboldt Foundation of University of Marburg from 1991 to 1993. Dr. Li obtained a Bachelor’s degree in Chemistry in July 1982, a Master of Science degree in July 1985 and a Ph.D. in Science in July 1988 from Peking University.

Yun Li Xue

Ms. Xue Yun Li is Senior Vice President, General Manager of Shandong Luye of Luye Pharma Group Ltd. From 1999 to 2009, she was the director of the R&D centre and then vice president of R&D of Shandong Luye. Prior to joining our Group, she was a technician and the chief of scientific research at Shenyang Liaohe Pharmaceutical Factory from 1988 to 1994. Ms. Xue obtained a Bachelor’s degree in Engineering from Jiamusi University in July 1988 and a Master’s degree in Integrated Traditional Chinese and Western Clinical Medicine from Shandong University of Traditional Chinese Medicine in July 2011.

Hua Jiang

Ms. Jiang Hua serves as Vice President, Head - International Business of the Company. Ms. Jiang has over 16 years of experience in international business development. Ms. Jiang holds a Doctor of Business Administration from United Business Institute in Belgium, a Master’s degree in Business Administration from KEDGE Business School (formerly known as Euromed Management School), and a Bachelor’s degree of Economics from Economy School, Fudan University. She is also an economist certified by the Ministry of Personnel of the People’s Republic of China (now the Ministry of Human Resources and Social Security of the People’s Republic of China).

Hui Xian Yuan

Mr. Yuan Hui Xian is Executive Director of Luye Pharma Group Ltd. Mr. Yuan was appointed as a Director in July 2003 and is in charge of our Group’s public relations. Prior to joining our Group in 1994, Mr. Yuan was a doctor with Shengli Petroleum Administrative Bureau Yantai Sanatorium from 1980 to 1994, where he was in charge of radiation diagnosis. From 1994 to 1999, Mr. Yuan was a deputy general manager with Shandong Luye. From 1999 to the incorporation of our Company in 2003, Mr. Yuan was the vice-president and executive director of Shandong Luye. He has also received a Post-graduate Certificate in National Economics from the China People’s University in February 2003. Mr. Yuan is the executive chairman of Luye Trading and a director of the following main subsidiaries of our Company: Shandong Luye, Nanjing Luye and Nanjing New AIGE Eggs Co. Ltd.. Mr. Yuan is a director of each of Luye Group, Luye Pharma Holdings, Luye Pharma Intl and Luye Pharma Investment.

Yuan Yuan Zhu

Ms. Zhu Yuan Yuan serves as Executive Director of the Company. She joined our Group in August 2009 and has 10 years of experience in corporate finance. Before joining our Group, she worked for New Asia Partners Investment Holdings Limited, a Shanghai and Hong Kong-based investment firm focused on assisting Chinese companies in accessing the international capital markets, principally by providing equity capital and corporate finance advisory services. She obtained her Master’s degree in Corporate Strategy and Governance from the University of Nottingham in December 2004 and a Bachelor’s degree in Finance from Southeast University, the PRC in June 2003. Ms. Zhu is a director of the following subsidiaries of our Company: Luye Pharma Hong Kong Limited, Solid Success Holdings Limited, Apex Group Holdings Limited and Kang Hai Pharmaceutical Technology Development Limited. She is a supervisor of our subsidiary, Beijing WPU. Ms. Zhu is a director of each of Luye Pharma Holdings, Luye Pharma Intl and Luye Pharma Investment.

Siu Kuen Lai

Ms. Lai Siu Kuen is Company Secretary of the Company. She is an associated director of TMF Hong Kong Limited (a company secretarial service provider).

Rui Lin Song

Mr. Song Rui Lin is Non-Executive Director of the Company. Mr. Song is the chairman of China Pharmaceutical Industry Research and Development Association and the executive deputy director of the Research Centre for Drug Policy and Industrial Development at China Pharmaceutical University. Mr. Song has extensive experience in the research of the PRC healthcare and drugs laws and policies, and was involved in the drafting and review of a number of the current PRC laws and regulations on healthcare and drugs. He is currently an independent non-executive Director of Shanghai Henlius Biotech, Inc., a company listed on the Main Board of Stock Exchange (stock code: 2696). From 1985 to 2007, Mr. Song served as deputy director, director and deputy head at the PRC State Council Legislative Office Subsequent to 2008, Mr. Song served as deputy director of the Chinese Pharmaceutical Association (the “Association”) and executive director of the Research Centre for Drug Policies the Association. He served as the chairman and executive editor of Chinese Journal of New Drugs Since 2011, Mr. Song has been serving as an expert at the Capital Healthcare Policy Reform Expert Group Mr. Song obtained a Bachelor of Laws degree from China University of Political Science and Law in 1985 and a Master in Business Administration degree from China Europe International Business School in 2004, and obtained a Doctorate in Social and Administrative Pharmacy from China Pharmaceutical University in 2018. Mr. Song is an independent director of Shanxi Zhendong Pharmaceutical Co., Ltd. an independent director of Jiangxi Boya Bio-pharmaceutical Co., Ltd. an independent director of Tibet Aim Pharm. Inc. and an independent Director of Shenzhen Chipscreen Biosciences Co., Ltd. Each of Shanxi Zhendong Pharmaceutical Co., Ltd., Jiangxi Boya Bio-pharmaceutical Co., Ltd. and Tibet Aim Pharm. Inc. is a company listed on the Shenzhen Stock Exchange. Shenzhen Chipscreen Biosciences Co., Ltd. is a company listed on the Shanghai Stock Exchange.

Sze Chung Choy

Dr. Choy Sze Chung serves as Non-Executive Independent Director of the Company. Dr. Choy has extensive experience in the securities industry and business management. He is currently the vice chairman of National Resources Securities Limited and the permanent honourable president and vice chairman of the Institute of Securities Dealers Ltd. Dr. Choy is a fellow member of the Hong Kong Institute of Directors, the Institute of Financial Accountants, the Institute of Public Accountants and the Institute of Compliance Officers and a member of the Society of Registered Financial Planners Limited. Dr. Choy is also a member of the Election Council for Hong Kong Deputies to the 12th and the 13th National People’s Congress of the People’s Republic of China, a member of the 4th and the 5th term Chief Executive Election Committee of Hong Kong and a member of Chinese People’s Political Consultative Conference, Shantou. Dr. Choy obtained a Master’s degree in Business Administration from University of Wales, Newport in October 2004 and a Master’s degree in Business Law from Monash University in April 2007, a Honorary doctorate of Management from Lincoln University in August 2018 and a Fellowship from Canadian Institute of Business Administration.

Man Kit Leung

Mr. Leung Man Kit serves as Non-Executive Independent Director of the Company. Mr. Leung has over 40 years of experience in project finance and corporate finance. Mr. Leung was appointed executive director and responsible officer of Unitas Holdings Limited (stock code: 8020) from September 2011 to November 2018. He is now a responsible officer of Grand Moore Capital Limited effective 18 September 2019. Previously, he was a director of Emerging Markets Partnership (Hong Kong) Limited, the principal adviser to the AIG Infrastructure Fund L.P. in 1999. He also held senior positions in the Hong Kong Branch of the Swiss Bank Corporation, SG Securities (HK) Limited (formerly known as Crosby Securities (Hong Kong) Limited) and Peregrine Capital Limited. Mr. Leung obtained a Bachelor’s degree in Social Sciences from University of Hong Kong in October 1977.

Yuk Lam Lo

Prof. Lo Yuk Lam is Independent Non-Executive Director of the Company. Professor Lo has extensive experience in biotechnology industry, corporate management, academic research and community service. Currently Professor Lo is serving as the Chairman of the Advisory Council for Food Safety of the Food and Health Bureau HKSAR, the Founding President of HK Bio-Med Innotech Association. Professor Lo is also the Honorary Founding Chairman of Hong Kong Bio-Organization, and a Committee Member of the Chinese Manufacturers’ Association of Hong Kong (CMA). In the educational area, Professor Lo has been elected an Honorary Fellow of the Hong Kong University of Science and Technology. He is an Honorary Chairman of Hong Kong Food Safety Association, Adjunct Professor of the Chinese University of Hong Kong and Honorary Professor of several universities in China. Professor Lo was heavily involved in several committees of the HKSAR Government. He had been appointed as Director of the Hong Kong Applied R&D Fund Co. Ltd., Chairman of the Biotechnology Committee of the Hong Kong Industry & Technology Development Council, and Chairman of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund, HKSAR. In Mainland China, Professor Lo is a member of Chinese People’s Political Consultative Conference in Jilin Province, and a consultant of the Centre for Disease Control and Prevention of China. In recognition of his leadership in the community and dedication to his field, Professor Lo has received many awards, including the prestigious “World’s outstanding Chinese Award” in 2008 and China’s “Top Ten Financial and Intelligent Persons” in 2007. Professor Lo was also awarded “Pericles International Prize” in 2019. He is the second Asian and the first person from Hong Kong to be awarded the Prize since it was founded in 1986.

Hua Qiao Zhang

Mr. Zhang Hua Qiao serves as Non-Executive Independent Director of the Company. Mr. Zhang has 16 years of experience in working in the investment banking industry since 1994. He served as managing director and the cohead of China research team from June 1999 to April 2006 and the deputy head of China investment banking division of UBS AG, Hong Kong Branch from September 2008 to June 2011. He graduated from the Graduate School of the People’s Bank of China with a Master’s degree in Economics in 1986, and from the Australian National University with a Master’s degree in Economics in January 1991.

Basic Compensation

Name Fiscal Year Total

Dian Bo Liu

3,759,000

Rong Bing Yang

2,711,000

Yuan Chong Liu

--

You Xin Li

--

Yun Li Xue

--

Hua Jiang

--

Hui Xian Yuan

1,345,000

Yuan Yuan Zhu

681,000

Siu Kuen Lai

--

Rui Lin Song

700,000

Sze Chung Choy

432,000

Man Kit Leung

485,000

Yuk Lam Lo

432,000

Hua Qiao Zhang

432,000
As Of  31 Dec 2019